Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Novo Nordisk’s Wegovy and Ozempic has been resolved.

Hims & Hers Health stock drops over 20% after the FDA removes semaglutide from the shortage list. Novo Nordisk launches a direct delivery service for Wegovy.

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Founded in 2018, Defiance is at the forefront of ETF innovation. Defiance is a leading ETF issuer specializing in thematic, ...

Although Hims & Hers is saying it will still make its own compounded GLP-1 drugs in 2025, it is up in the air whether the U.S. government or court systems will allow the company to sell these ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

He started out by commenting that “the government has historically not been ... by 218 percentage points (see more details here). Hims & Hers Health, Inc. (NYSE:HIMS) is a technology company ...

Andrew Dudum is making it abundantly clear Hims is a healthcare company, not a cosmetic wellness brand. Ms. Manuel is a foreign policy expert and former U.S. government official who specializes in ...

In this article, we are going to take a look at where Hims & Hers Health ... He started out by commenting that “the government has historically not been able to take on this group.